Eidos Therapeutics completes $64M Series B financing

Funding supports Phase 2 clinical trials of AG10, a potential best-in-class therapy for transthyretin amyloidosis, and ongoing preparation for Phase 3 clinical trials SAN FRANCISCO, April 5, 2018 -- (Healthcare Sales & Marketing Network) -- Eidos Thera... Biopharmaceuticals, Venture Capital Eidos Therapeutics, transthyretin amyloidosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news